Intrexon Target of Unusually High Options Trading (XON)

Intrexon Corp (NYSE:XON) saw unusually large options trading activity on Monday. Traders purchased 10,441 call options on the company. This is an increase of approximately 3,103% compared to the average volume of 326 call options.

In related news, insider Helen Sabzevari sold 8,402 shares of the firm’s stock in a transaction that occurred on Wednesday, July 18th. The shares were sold at an average price of $14.54, for a total value of $122,165.08. Following the transaction, the insider now owns 25,000 shares of the company’s stock, valued at $363,500. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Randal J. Kirk acquired 7,479,431 shares of the company’s stock in a transaction that occurred on Tuesday, July 3rd. The stock was acquired at an average cost of $13.37 per share, for a total transaction of $99,999,992.47. The disclosure for this purchase can be found here. Company insiders own 48.20% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Peregrine Capital Management LLC raised its stake in Intrexon by 15.7% during the 2nd quarter. Peregrine Capital Management LLC now owns 711,266 shares of the biotechnology company’s stock worth $9,915,000 after acquiring an additional 96,393 shares during the period. Wellington Shields & Co. LLC raised its stake in Intrexon by 9.7% during the 2nd quarter. Wellington Shields & Co. LLC now owns 335,600 shares of the biotechnology company’s stock worth $4,678,000 after acquiring an additional 29,600 shares during the period. Northern Trust Corp raised its stake in Intrexon by 9.7% during the 1st quarter. Northern Trust Corp now owns 411,324 shares of the biotechnology company’s stock worth $6,305,000 after acquiring an additional 36,508 shares during the period. Chessman Wealth Strategies RIA bought a new stake in Intrexon during the 2nd quarter worth approximately $205,000. Finally, Millennium Management LLC raised its stake in Intrexon by 203.2% during the 1st quarter. Millennium Management LLC now owns 298,737 shares of the biotechnology company’s stock worth $4,580,000 after acquiring an additional 200,193 shares during the period. Institutional investors own 84.92% of the company’s stock.

NYSE XON opened at $19.07 on Tuesday. Intrexon has a 12 month low of $10.26 and a 12 month high of $20.49. The company has a market cap of $1.87 billion, a price-to-earnings ratio of -20.73 and a beta of 1.09. The company has a current ratio of 1.78, a quick ratio of 1.53 and a debt-to-equity ratio of 0.01.

Intrexon (NYSE:XON) last released its earnings results on Thursday, August 9th. The biotechnology company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.28). Intrexon had a negative return on equity of 16.67% and a negative net margin of 82.17%. The firm had revenue of $45.30 million for the quarter, compared to the consensus estimate of $51.70 million. During the same quarter in the previous year, the business posted ($0.16) EPS. analysts expect that Intrexon will post -0.79 earnings per share for the current year.

XON has been the topic of a number of research reports. ValuEngine raised shares of Intrexon from a “strong sell” rating to a “sell” rating in a report on Monday, August 20th. Zacks Investment Research raised shares of Intrexon from a “hold” rating to a “buy” rating and set a $16.00 price objective on the stock in a report on Thursday, August 16th. Bank of America downgraded shares of Intrexon from a “neutral” rating to an “underperform” rating and set a $12.00 price objective on the stock. in a report on Monday, July 16th. Finally, Stifel Nicolaus initiated coverage on shares of Intrexon in a report on Tuesday, July 17th. They issued a “buy” rating and a $72.00 price objective on the stock. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company. Intrexon currently has an average rating of “Buy” and an average price target of $33.14.

Intrexon Company Profile

Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms.

Further Reading: Understanding Price to Earnings Ratio (PE)

Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply